{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:27Z","timestamp":1740185007430,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00292-024-01347-0","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:03:27Z","timestamp":1723035807000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das muskelinvasive und metastasierte Urothelkarzinom der Harnblase","Muscle-invasive and metastatic urothelial carcinoma of the urinary bladder"],"prefix":"10.1007","volume":"45","author":[{"given":"Simone","family":"Bertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Bahlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-3349","authenticated-orcid":false,"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"1347_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","volume":"75","author":"M Abufaraj","year":"2019","unstructured":"Abufaraj\u00a0M, Foerster\u00a0B, Schernhammer\u00a0E et\u00a0al (2019) Micropapillary urothelial carcinoma of the bladder: a\u00a0systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol 75:649\u2013658","journal-title":"Eur Urol"},{"key":"1347_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng.3503","volume":"48","author":"HA Al-Ahmadie","year":"2016","unstructured":"Al-Ahmadie\u00a0HA, Iyer\u00a0G, Lee\u00a0BH et\u00a0al (2016) Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet 48:356\u2013358","journal-title":"Nat Genet"},{"key":"1347_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"AJ Witjes","year":"2024","unstructured":"Witjes\u00a0AJ, Bruins\u00a0MH, Carrion\u00a0A et\u00a0al (2024) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85:17\u201331","journal-title":"Eur Urol"},{"key":"1347_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00000478-199405000-00005","volume":"18","author":"MB Amin","year":"1994","unstructured":"Amin\u00a0MB, Ro\u00a0JY, Lee\u00a0KM et\u00a0al (1994) Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol 18:466\u2013473","journal-title":"Am J Surg Pathol"},{"key":"1347_CR5","volume-title":"WHO classification of tumours editorial board. Urinary and male genital tumours","author":"Anonymous","year":"2022","unstructured":"Anonymous (2022) WHO classification of tumours editorial board. Urinary and male genital tumours. International Agency for Research on Cancer"},{"key":"1347_CR6","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. New Engl J Med 384:2102\u20132114","journal-title":"New Engl J Med"},{"key":"1347_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt\u00a0J, de Wit\u00a0R, Vaughn\u00a0DJ et\u00a0al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N\u00a0Engl J Med 376:1015\u20131026","journal-title":"N Engl J Med"},{"key":"1347_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/his.14206","volume":"77","author":"S Bertz","year":"2020","unstructured":"Bertz\u00a0S, Stohr\u00a0R, Gaisa\u00a0NT et\u00a0al (2020) TERT promoter mutation analysis as a\u00a0surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder. Histopathology 77:949\u2013962","journal-title":"Histopathology"},{"key":"1347_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1464-410X.2009.09166.x","volume":"106","author":"C Bolenz","year":"2010","unstructured":"Bolenz\u00a0C, Herrmann\u00a0E, Bastian\u00a0PJ et\u00a0al (2010) Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a\u00a0multicentre validation trial. BJU Int 106:493\u2013499","journal-title":"BJU Int"},{"key":"1347_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JU.0000000000001855","volume":"206","author":"NH Chakiryan","year":"2021","unstructured":"Chakiryan\u00a0NH, Jiang\u00a0DD, Gillis\u00a0KA et\u00a0al (2021) Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer. J\u00a0Urol 206:924\u2013932","journal-title":"J Urol"},{"key":"1347_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/cncr.20456","volume":"101","author":"L Cheng","year":"2004","unstructured":"Cheng\u00a0L, Pan\u00a0CX, Yang\u00a0XJ et\u00a0al (2004) Small cell carcinoma of the urinary bladder: a\u00a0clinicopathologic analysis of 64\u00a0patients. Cancer 101:957\u2013962","journal-title":"Cancer"},{"key":"1347_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3109\/00313025.2010.522173","volume":"42","author":"E Comperat","year":"2010","unstructured":"Comperat\u00a0E, Roupret\u00a0M, Yaxley\u00a0J et\u00a0al (2010) Micropapillary urothelial carcinoma of the urinary bladder: a\u00a0clinicopathological analysis of 72\u00a0cases. Pathology 42:650\u2013654","journal-title":"Pathology"},{"key":"1347_CR13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","volume":"189","author":"F Dayyani","year":"2013","unstructured":"Dayyani\u00a0F, Czerniak\u00a0BA, Sircar\u00a0K et\u00a0al (2013) Plasmacytoid urothelial carcinoma, a\u00a0chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J\u00a0Urol 189:1656\u20131661","journal-title":"J Urol"},{"key":"1347_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/BLC-190258","volume":"6","author":"LN Diamantopoulos","year":"2020","unstructured":"Diamantopoulos\u00a0LN, Khaki\u00a0AR, Grivas\u00a0P et\u00a0al (2020) Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. BLC 6:71\u201381","journal-title":"BLC"},{"key":"1347_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.21037\/atm.2019.10.24","volume":"7","author":"M Eckstein","year":"2019","unstructured":"Eckstein\u00a0M, Cimadamore\u00a0A, Hartmann\u00a0A et\u00a0al (2019) PD-L1 assessment in urothelial carcinoma: a\u00a0practical approach. Ann Transl Med 7:690","journal-title":"Ann Transl Med"},{"key":"1347_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","volume":"7","author":"M Eckstein","year":"2024","unstructured":"Eckstein\u00a0M, Matek\u00a0C, Wagner\u00a0P et\u00a0al (2024) Proposal for a\u00a0novel histological scoring system as a\u00a0potential grading approach for muscle-invasive urothelial bladder cancer correlating with disease aggressiveness and patient outcomes. Eur Urol Oncol 7:128\u2013138","journal-title":"Eur Urol Oncol"},{"key":"1347_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.pas.0000147396.08853.26","volume":"29","author":"A Fleischmann","year":"2005","unstructured":"Fleischmann\u00a0A, Thalmann\u00a0GN, Markwalder\u00a0R et\u00a0al (2005) Prognostic implications of extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the bladder. Am J Surg Pathol 29:89\u201395","journal-title":"Am J Surg Pathol"},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.humpath.2020.09.010","volume":"106","author":"L Han","year":"2020","unstructured":"Han\u00a0L, Gallan\u00a0AJ, Steinberg\u00a0GD et\u00a0al (2020) Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol 106:54\u201361","journal-title":"Hum Pathol"},{"key":"1347_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun\u00a0A, De Reynies\u00a0A, Allory\u00a0Y et\u00a0al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420\u2013433","journal-title":"Eur Urol"},{"key":"1347_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/iju.12729","volume":"22","author":"D Kaushik","year":"2015","unstructured":"Kaushik\u00a0D, Frank\u00a0I, Boorjian\u00a0SA et\u00a0al (2015) Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 22:549\u2013554","journal-title":"Int J Urol"},{"key":"1347_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo\u00a0N, Shariat\u00a0SF, Guo\u00a0CC et\u00a0al (2020) What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 6:653\u2013663","journal-title":"Eur Urol Focus"},{"key":"1347_CR22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles\u00a0T, Park\u00a0SH, Voog\u00a0E et\u00a0al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 383:1218\u20131230","journal-title":"N Engl J Med"},{"key":"1347_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng\u00a0X, Yan\u00a0X, Wang\u00a0L et\u00a0al (2021) Open-label, multicenter, phase\u00a0II study of RC48-ADC, a\u00a0HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 27:43\u201351","journal-title":"Clin Cancer Res"},{"key":"1347_CR24","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","volume":"27","author":"AO Siefker-Radtke","year":"2009","unstructured":"Siefker-Radtke\u00a0AO, Kamat\u00a0AM, Grossman\u00a0HB et\u00a0al (2009) Phase\u00a0II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer. J\u00a0Clin Oncol 27:2592\u20132597","journal-title":"J Clin Oncol"},{"key":"1347_CR25","doi-asserted-by":"crossref","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Bernardo C et\u00a0al (2022) Molecular subtypes as a\u00a0basis for stratified use of neoadjuvant chemotherapy for muscle-invasive bladder cancer\u2011a narrative review. Cancers 14:","DOI":"10.3390\/cancers14071692"},{"key":"1347_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41379-020-0453-z","volume":"33","author":"AS Taylor","year":"2020","unstructured":"Taylor\u00a0AS, Mckenney\u00a0JK, Osunkoya\u00a0AO et\u00a0al (2020) PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a\u00a0clinicopathologic study with immunohistochemical and molecular correlates. Mod Pathol 33:1165\u20131171","journal-title":"Mod Pathol"},{"key":"1347_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.eururo.2010.01.015","volume":"58","author":"D Tilki","year":"2010","unstructured":"Tilki\u00a0D, Reich\u00a0O, Karakiewicz\u00a0PI et\u00a0al (2010) Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol 58:112\u2013117","journal-title":"Eur Urol"},{"key":"1347_CR28","doi-asserted-by":"crossref","unstructured":"Weyerer V, Eckstein M, Comperat E et\u00a0al (2020) Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the prototype of an FGFR3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype. Cancers 12:","DOI":"10.3390\/cancers12030763"},{"key":"1347_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/his.13958","volume":"75","author":"V Weyerer","year":"2019","unstructured":"Weyerer\u00a0V, Weisser\u00a0R, Moskalev\u00a0EA et\u00a0al (2019) Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology 75:865\u2013875","journal-title":"Histopathology"},{"key":"1347_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","volume":"193","author":"DL Willis","year":"2015","unstructured":"Willis\u00a0DL, Fernandez\u00a0MI, Dickstein\u00a0RJ et\u00a0al (2015) Clinical outcomes of cT1 micropapillary bladder cancer. J\u00a0Urol 193:1129\u20131134","journal-title":"J Urol"},{"key":"1347_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","volume":"80","author":"U Zinnall","year":"2018","unstructured":"Zinnall\u00a0U, Weyerer\u00a0V, Comperat\u00a0E et\u00a0al (2018) Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum Pathol 80:55\u201364","journal-title":"Hum Pathol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-024-01347-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:58:14Z","timestamp":1729850294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-024-01347-0"}},"subtitle":["Aktueller Stand histopathologischer, molekularer und immunologischer Prognose- und Pr\u00e4diktionsfaktoren","Current state of histopathologic, molecular, and immunologic prognostic and predictive factors"],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s00292-024-01347-0","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"type":"print","value":"2731-7188"},{"type":"electronic","value":"2731-7196"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"8 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"<b>V.\u00a0Bahlinger<\/b>\u00a0Honorare von MSD und Janssen. Forschungsf\u00f6rderung von Gilead Sciences. <b>A.\u00a0Hartmann<\/b> Honorare von Eisai, Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, 3DHistotech; Beratungsgeb\u00fchren von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech; Forschungsf\u00f6rderung von AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche. <b>M.\u00a0Eckstein<\/b> Honorare und Reisekosten von Eisai, MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS; Forschungsf\u00f6rderung von AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH; Beratungsgeb\u00fchren von Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS. S.\u00a0Bertz und F.\u00a0Lange geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}